Home / Stocks / AHCO

AdaptHealth (AHCO, Health Care Distributors) Stock Valuation & Fair Value Significantly overvalued

AdaptHealth (AHCO, Health Care Distributors) trades at a blended P/E of 218.8, far above its historical normal valuation, with a forward growth estimate of 67.6% and a PEG of 3.24. Analysts' one-year estimates have been hit 33% of the time.

DATA AS OF 2026-09-21
Blended P/E
218.8
Normal P/E
16.7
PEG
3.24
Fwd growth
67.6%
Div yield
0.0%
RSI (14)
41.3
Neutral

The Street vs SeerForecast

Wall Street's mean price target for AHCO is $9.00 across 7 analysts, 57.9% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from fairly valued (2026-07-31) to significantly overvalued (2026-09-05).

Blended P/E and rating by weekBlended P/E moved from 13.6 to 78.5 between 2026-07-31 and 2026-09-05, against a normal P/E of 16.7, with 1 rating change over 13 recorded weeks.2026-07-31: P/E 13.6, Fairly valued (recalculated)2026-08-03: P/E 13.7, Fairly valued2026-08-07: P/E 13.7, Fairly valued (recalculated)2026-08-10: P/E 46.9, Significantly overvalued2026-08-14: P/E 46.9, Significantly overvalued (recalculated)2026-08-17: P/E 55.0, Significantly overvalued2026-08-21: P/E 55.0, Significantly overvalued (recalculated)2026-08-24: P/E 62.8, Significantly overvalued2026-08-27: P/E 62.8, Significantly overvalued (recalculated)2026-08-28: P/E 62.8, Significantly overvalued (recalculated)2026-08-30: P/E 62.8, Significantly overvalued (recalculated)2026-08-31: P/E 78.5, Significantly overvalued2026-09-05: P/E 78.5, Significantly overvalued (recalculated)20.040.060.0Jul 31Aug 9Aug 18Aug 27Sep 5Normal P/E 16.7
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 13.6-19%Fairly valued
2026-08-10P/E 46.9+181%Significantly overvalued
2026-08-31P/E 78.5+370%Significantly overvalued
2026-09-05P/E 78.5+370%Significantly overvalued ← now

Frequently asked questions

Is AdaptHealth stock overvalued?

At a blended P/E of 218.8 versus its historical normal P/E of 16.7, AdaptHealth trades far above its typical valuation, with a PEG of 3.24 on 67.6% forward growth. tickerseer currently rates it significantly overvalued.

What is AdaptHealth's fair value and PEG?

AdaptHealth trades at a blended P/E of 218.8 against a historical normal P/E of 16.7, a PEG of 3.24, and a forward growth estimate of 67.6%.

Has tickerseer's rating of AdaptHealth changed?

tickerseer's rating moved from fairly valued (2026-07-31) to significantly overvalued (2026-09-05).

What is the analyst price target for AdaptHealth?

The mean Wall Street price target for AdaptHealth is $9.00 across 7 analysts, 57.9% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Health Care Distributors. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track AHCO free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.